Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
Drs Lynne Fehrenbacher and Leah Leonard-Kandarapally join Ethics Talk to discuss key roles of infectious disease pharmacists in antimicrobial stewardship.
The conventional quality-adjusted life years approach to resource allocation has greater societal value if it is distributed among many rather than concentrated on a few, assuming that severity of illness is the same.
Amy Fairchild, PhD, MPH, Ronald Bayer, PhD, and James Colgrove, PhD, MPH
A brief history of public opposition to disease surveillance in the U.S., despite the documented success of this tool in recognizing and managing threats to public health.